By Market Intelligence Team

Biocon Biologics Ltd. (Biocon Biologics), a subsidiary of Biocon Ltd. has entered into a definitive agreement to acquire its partner Viatris Inc. for about $3.3 billion composed of a $2.3 billion cash payment and about $1 billion shares of Biocon Biologics stock. The cash payment will take place with $2 billion to be paid at closing and $335 million to be paid during 2024. The goal is to create a fully integrated global biosimilars enterprise. The deal is slated to close during the second half of 2022. Biocon Biologics currently has a portfolio of 20 biosimilars. The acquisition of biosimilars…
Content Restricted

You must be a Free or Elite member to view this resource.

Log In | Sign up or learn more about membership options.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!